Indivior announces findings from real-world evidence from study on Sublocade

Indivior (INDV) Pharmaceuticals announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to Sublocade, a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder. These outcomes were more favorable compared to both patients adherent to other medications for OUD and to those who were nonadherent to MOUD. “These data highlight the potential of long-acting injectable buprenorphine treatment to improve care continuity for people living with OUD and reduce the need for acute, high-cost healthcare services,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior.